País: Singapur
Idioma: anglès
Font: HSA (Health Sciences Authority)
BLACK SNAKE ANTIVENOM
UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED
J06AA03
18000 u/vial
INJECTION
INTRAVENOUS, SUBCUTANEOUS, INTRAMUSCULAR
Prescription Only
CSL LTD
1992-03-23
PRODUCT INFORMATION NAME OF THE MEDICINE POLYVALENT SNAKE ANTIVENOM (AUSTRALIA - PAPUA NEW GUINEA) AUST R 74899 DESCRIPTION POLYVALENT SNAKE ANTIVENOM contains antibodies to the venom of the following snakes: King brown snake _(Pseudechis australis)_ Tiger snake _(Notechis scutatus)_ Brown snake _(Pseudonaja textilis)_ Death adder _(Acanthophis antarcticus)_ Taipan _(Oxyuranus scutellatus)_ The antivenom is prepared from the plasma of horses immunised with the venom of the snakes. The amount of antivenom has been standardised to neutralise _in_ _vitro _the average yield of venom from each snake. The minimum amount of each antivenom is as follows: King brown snake antivenom 18,000 units Taipan antivenom 12,000 units Death adder antivenom 6,000 units Tiger snake antivenom 3,000 units Brown snake antivenom 1,000 units Total 40,000 units The product also contains phenol, sodium chloride and other equine plasma proteins in an aqueous solution. PHARMACOLOGY The venoms of some snakes from Australia and Papua New Guinea contain neurotoxins which can cause respiratory paralysis, and coagulants (except in the death adder) which convert prothrombin to thrombin, which in turn produces a secondary afibrinogenaemia with resultant haemorrhage. The venoms of some snakes also contain a myolytic toxin which can cause renal failure. Although the amount of antivenom in each dose of POLYVALENT SNAKE ANTIVENOM will neutralise the average yield of venom from each snake _in vitro_, the actual amount needed in clinical practice may be considerably more, particularly if treatment is delayed and the effects of the venom are already evi Llegiu el document complet